Definitive Healthcare (NASDAQ:DH) Releases Q2 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its second quarter earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.09 for the period, compared to the consensus estimate of $0.09. The company issued revenue guidance of $63.7 million, compared to the consensus revenue estimate of $62.68 million. Definitive Healthcare also updated its FY24 guidance to $0.32-0.34 EPS.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH traded down $0.23 on Tuesday, reaching $5.74. The company’s stock had a trading volume of 3,706,127 shares, compared to its average volume of 710,079. Definitive Healthcare has a 52-week low of $4.38 and a 52-week high of $11.97. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.30 and a current ratio of 2.30. The company has a 50-day simple moving average of $5.55 and a 200 day simple moving average of $7.17. The company has a market cap of $676.92 million, a P/E ratio of -3.28, a PEG ratio of 4.36 and a beta of 1.30.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Tuesday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.04). The firm had revenue of $63.48 million during the quarter, compared to the consensus estimate of $64.00 million. Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. As a group, equities research analysts anticipate that Definitive Healthcare will post 0.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DH. Barclays decreased their price target on shares of Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating for the company in a research note on Thursday, May 9th. Needham & Company LLC reiterated a hold rating on shares of Definitive Healthcare in a report on Wednesday, May 8th. Canaccord Genuity Group lowered their target price on shares of Definitive Healthcare from $10.00 to $8.00 and set a hold rating for the company in a research note on Wednesday, May 8th. Stifel Nicolaus dropped their price target on Definitive Healthcare from $11.00 to $9.50 and set a buy rating on the stock in a research note on Wednesday, May 8th. Finally, Morgan Stanley downgraded shares of Definitive Healthcare from an overweight rating to an equal weight rating and dropped their price objective for the company from $11.50 to $9.00 in a report on Wednesday, May 8th. Eight investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $9.56.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.